Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 601–700 of 1,000
Karlowsky, J. A., Adam, H. J., Baxter, M. R., Dutka, C. W., Nichol, K. A., Laing, N. M., Golding, G. R., & Zhanel, G. G. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa118 · Cited by 21
Systematic review on the definition and predictors of severe Clostridiodes difficile infection
Zhang, V. R., Woo, A. S. J., Scaduto, C., Kasunuran-Cruz, M. T., Tan, Y. Y., Du, H. Y., Feng, M., & Siah, K. T. H. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15102 · Cited by 21
Detection of Clostridioides difficile by Real-time PCR in Young Children Does Not Predict Disease
Pahud, B. A., Hassan, F., Harrison, C. J., Halasa, N., Chappell, J. D., Englund, J. A., Klein, E. J., Szilagyi, P. G., Weinberg, G. A., Sherman, A., et al. (2020) · Hospital Pediatrics · doi:10.1542/hpeds.2020-0012 · Cited by 21
Self-citationChoy, A. M., & Freedberg, D. E. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820939447 · Cited by 23
Yang, Z., Huang, Q., Qin, J., Zhang, X., Jian, Y., Lv, H., Liu, Q., & Li, M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.578098 · Cited by 23
The gut microbiome: what every gastroenterologist needs to know
Mullish, B. H., Quraishi, M. N., Segal, J. P., Ianiro, G., & Iqbal, T. H. (2020) · Frontline Gastroenterology · doi:10.1136/flgastro-2019-101376 · Cited by 25
Role of Metronidazole in Mild Clostridium difficile Infections
Fabre, V., Dzintars, K., Avdic, E., & Cosgrove, S. E. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy474 · Cited by 21
Effective approaches to diagnostic stewardship of syndromic molecular panels
Hitchcock, M. M., Gomez, C. A., Pozdol, J., & Banaei, N. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad063 · Cited by 20
Causal role of the gut microbiome in certain human diseases: a narrative review
Prosty, C. J., Katergi, K., Papenburg, J., Lawandi, A., Lee, T. C., Shi, H., Burnham, P., Swem, L. R., Routy, B., Yansouni, C. P., et al. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100086 · Cited by 24
“43 However, caution must be exercised because cases of fatal bacteremia secondary to FMT have been documented.”
Jamil, E., Saleem, Z., Godman, B., Ullah, M., Amir, A., Haseeb, A., Meyer, J. C., Qamar, M. U., & Abuhussain, S. S. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1600787 · Cited by 31
Bilinskaya, A., Goodlet, K. J., & Nailor, M. D. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.04.009 · Cited by 20
Whyte, C., Alhasani, H., Caplan, R. J., & Tully, A. P. (2019) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2019.105641 · Cited by 22
Learning from Nature: Bacterial Spores as a Target for Current Technologies in Medicine (Review)
Andryukov, B. G., Karpenko, A. A., & Lyapun, I. N. (2020) · Современные технологии в медицине · doi:10.17691/stm2020.12.3.13 · Cited by 21
Willis, D. N., Huang, F. S., Elward, A. M., Wu, N., Magnusen, B., Dubberke, E. R., & Hayashi, R. J. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa090 · Cited by 20
“The vast majority of infections were classified as healthcare associated, by Centers for Disease Control and Prevention (CDC) definitions [15].”
BackgroundSelf-citationEyre, D. W., Laager, M., Walker, A. S., Cooper, B. S., Wilson, D. J., & (MInD-Healthcare), O. B. O. T. C. M. I. D. I. H. P. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008417 · Cited by 20
Frontiers in antibiotic alternatives for Clostridioides difficile infection
Phanchana, M., Harnvoravongchai, P., Wongkuna, S., Phetruen, T., Phothichaisri, W., Panturat, S., Pipatthana, M., Charoensutthivarakul, S., Chankhamhaengdecha, S., & Janvilisri, T. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i42.7210 · Cited by 24
Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection
Łukawska, A., & Mulak, A. (2022) · Polish Journal of Microbiology · doi:10.33073/pjm-2022-007 · Cited by 20
“However, while vancomycin eliminates C. diffi cile vegetative forms, it does not influence endospores (McDonald et al. 2018).”
BackgroundClostridioides difficile in Latin America: A comprehensive review of literature (1984–2021)
Acuña-Amador, L., Quesada-Gómez, C., & Rodríguez, C. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102547 · Cited by 22
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
Vasavada, S. R., Panneerselvam, K., Amin, R., Varatharajalu, K., Okhuysen, P. C., Oliva, I. C. G., Wang, J., Grivas, P., Thomas, A. S., & Wang, Y. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0722 · Cited by 22
Sivasankar, S., Goldman, J. L., & Hoffman, M. A. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac128 · Cited by 19
Rubak, T., Baunwall, S. M. D., Gregersen, M., Hansen, T. K., Rosenbæk, J. B., Erikstrup, L. T., Hvas, C. L., & Damsgaard, E. M. S. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00772-3 · Cited by 21
Okafor, C. M., Clogher, P., Olson, D. M., Niccolai, L. M., & Hadler, J. L. (2023) · Emerging infectious diseases · doi:10.3201/eid2905.221294 · Cited by 20
“org/journal/eid; and (4) view/print certificate.”
BackgroundJanardhanan, J., Kim, C. K., Qian, Y., Yang, J., Meisel, J. E., Ding, D., Speri, E., Schroeder, V. A., Wolter, W. R., Oliver, A. G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304110120 · Cited by 20
Clostridium difficile Screening for Colonization During an Outbreak Setting
Linsenmeyer, K. D., O’Brien, W., Brecher, S. M., Strymish, J. M., Rochman, A., Itani, K. M. F., & Gupta, K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy455 · Cited by 20
Blanco, N., O’Hara, L. M., Robinson, G. L., Brown, J., Heil, E. L., Brown, C. H., Stump, B. D., Sigler, B. W., Belani, A., Miller, H. L., et al. (2018) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.04.204 · Cited by 21
Solanky, D., Pardi, D. S., Loftus, E. V., & Khanna, S. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy291 · Cited by 22
“Not given medication 33 (47) 23 (33) 47 (67) 9 (13) 30 (43) 26 (37) 38 (54) 18 (26)”
Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile
van Eijk, E., Boekhoud, I. M., Kuijper, E. J., Sanders, I. M. J. G., Wright, G. E., & Smits, W. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01363-18 · Cited by 20
Tabbaa, O. M., Aboelsoud, M. M., & Mattar, M. C. (2018) · Gastroenterology Research · doi:10.14740/gr1091 · Cited by 22
Clostridium difficile in Asia: Opportunities for One Health Management
Collins, D. A., & Riley, T. V. (2018) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4010007 · Cited by 20
“No diagnostic test besides CCCA is suitable as a stand-alone test since toxin EIAs have low sensitivity, and PCR, GDH EIA and culture cannot rule out cases of transient colonisation [26].”
Madden, G. R., & Sifri, C. D. (2019) · Annals of Transplantation · doi:10.12659/aot.915168 · Cited by 20
The rate and importance of Clostridium difficile in colorectal cancer patients.
Jahani-Sherafat, S., Azimirad, M., Alebouyeh, M., Amoli, H. A., Hosseini, P., Ghasemian-Safaei, H., & Moghim, S. (2019) · Gastroenterology and hepatology from bed to bench. · Cited by 26
Lin, T.-C., Hung, Y., Ko, W., & Ruan, J. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.08.009 · Cited by 20
Lee, A. A., Rao, K. K., Limsrivilai, J., Gillilland, M. G., Malamet, B. J., Briggs, E., Young, V. B., & Higgins, P. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz335 · Cited by 21
You, J. H. S., Jiang, X., Lee, W. H., Chan, P. K. S., & Ng, S. C. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15002 · Cited by 25
Viel‐Thériault, I., Bettolli, M., Toye, B., Harrison, M., & Saux, N. L. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002420 · Cited by 19
“Fluoroquinolones use has increasingly been associated with adverse events, including Clostridium difficile infection and the rapid emergence of resistance in Gram-negative bacilli.(22) For these reasons, our local guideline for appendicitis management has recommended the use of ampicillin, tobramycin or gentamicin and…”
BackgroundAktualisierte S3-Leitlinie Colitis ulcerosa
Kucharzik, T. F., Dignass, A. U., Atreya, R. N., Bokemeyer, B., Esters, P., Herrlinger, K. R., Kannengießer, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1015-7265 · Cited by 33
Saldanha, G. Z., Pires, R. N., Rauber, A. P., de Lima-Morales, D., Falci, D. R., Caierão, J., Pasqualotto, A. C., & Martins, A. F. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.01.007 · Cited by 19
Voth, E. R., & Khanna, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1752192 · Cited by 23
Azimirad, M., Yadegar, A., Gholami, F., Shahrokh, S., Aghdaei, H. A., Ianiro, G., Suzuki, H., Cammarota, G., & Zali, M. R. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s265520 · Cited by 20
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
Kullar, R., Tran, M.-C. N., & Goldstein, E. J. C. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s242959 · Cited by 19
“This article provides an overview of developing drugs that may have a potential role in the treatment of CDI.”
InfluentialPal, R., Dai, M., & Seleem, M. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-90314-3 · Cited by 19
Optimizing preoperative antibiotics in patients with β-lactam allergies: A role for pharmacy
Kwiatkowski, S., Mulugeta, S., Davis, S. L., Kenney, R. M., Kalus, J. S., Walton, L., & Patel, N. B. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab218 · Cited by 22
“colitis.(13) Allergic reaction was defined as a type I hypersensitivity reaction, cytotoxic reaction, serum sickness, drug reaction with eosinophilia and systemic symptoms, severe cutaneous adverse reaction, or toxic epidermal necrolysis within 7 days of preoperative antibiotic administration.”
BackgroundUpdate on gut microbiota in gastrointestinal diseases
Nishida, A., Nishino, K., Ohno, M., Sakai, K., Owaki, Y., Noda, Y., & Imaeda, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i22.7653 · Cited by 25
Clostridioides difficile as a Potential Pathogen of Importance to One Health: A Review
Mitchell, M., Nguyen, S. V., Macori, G., Bolton, D., McMullan, G., Drudy, D., & Fanning, S. (2022) · Foodborne Pathogens and Disease · doi:10.1089/fpd.2022.0037 · Cited by 23
“Following the collection of a stool sample, the best method for C. difficile detection is a toxin test by NAAT (nucleic acid amplification test) and/or in conjunction with a GDH (glutamate dehydrogenase) plus toxin test according to the 2017 update from the Infectious Diseases Society of America (IDSA) and the Society f…”
Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection
Feuerstadt, P., Allegretti, J. R., & Khanna, S. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002195 · Cited by 19
Box, M. J., Ortwine, K., Goicoechea, M., & (SASP), S. A. S. P. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy192 · Cited by 19
“Recent CDI guidelines affirm the need to use caution in applying study results with an abnormally high baseline incidence of CDI and conclude that there are insufficient data at this time to recommend probiotics for primary prevention of CDI outside of clinical trials [1].”
BackgroundThabit, A. K., Varugehese, C. A., & Levine, A. R. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.06.016 · Cited by 19
Elangovan, A., Allegretti, J. R., & Fischer, M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1673725 · Cited by 18
Karaoui, W. R., Rustam, L. B., Daher, H. B., Rimmani, H. H., Rasheed, S., Matar, G. M., Mahfouz, R. A., Araj, G. F., Zahreddine, N. K., Kanj, S. S., et al. (2019) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2019.11.005 · Cited by 19
Screening for potent and selective anticlostridial leads among FDA-approved drugs
AbdelKhalek, A., Mohammad, H. T., Mayhoub, A. S., & Seleem, M. N. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0288-3 · Cited by 19
Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile
Hamada, M., Yamaguchi, T., Ishii, Y., Chono, K., & Tateda, K. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.02.014 · Cited by 18
Singh, T., Bedi, P. S., Bumrah, K., Gandhi, D., Arora, T., Verma, N., Schleicher, M. C., Rai, M. P., Garg, R., Verma, B. R., et al. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001610 · Cited by 19
Toxin‐Producing Klebsiella oxytoca in Healthy Infants
Greimel, T. M., Stampfer, L., Leitner, E., Kienesberger, S., Zechner, E. L., Bozic, M., Wagner, G. E., Unterhauser, K., Kitsera, M., Hauer, A. C., et al. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003299 · Cited by 19
Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature
Adams, D. J., Barone, J. B., & Nylund, C. M. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab064 · Cited by 19
Feuerstadt, P., Nelson, W. W., Teigland, C. L., & Dahdal, D. N. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.2 · Cited by 21
Tilton, C., & Johnson, S. W. (2018) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.08.021 · Cited by 19
“They also state that there are insufficient data to support asymptomatic isolation or discontinuation of PPIs for CDI prevention.(3) However, all institutions should employ traditional infection prevention strategies (eg, hand hygiene and the wearing of gloves and gowns when entering the room of someone with CDI).”
BackgroundMethodInfluentialSelf-citationGonzalez-Orta, M. I., Saldana, C. S., Ng-Wong, Y. K., Cadnum, J. L., Jencson, A. L., Jinadatha, C., & Donskey, C. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz189 · Cited by 18
Sandlund, J., Estis, J., Katzenbach, P., Nolan, N., Hinson, K. R., Herres, J. A., Pero, T., Peterson, G., Schumaker, J.-M., Stevig, C., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00945-19 · Cited by 18
“0°C), white blood cell (WBC) count, creatinine, CDI severity classification (4), CDI treatment, admittance to an intensive care unit (ICU), length of stay, resolution of symptoms within 14 days, and 30-day CDI relapse.”
BackgroundInfluentialIn vitro activity of eravacycline against common ribotypes of Clostridioides difficile
Bassères, E., Begum, K., Lancaster, C. K., Gonzales-Luna, A. J., Carlson, T. J., Miranda, J. M., Rashid, T., Alam, M. J., Eyre, D. W., Wilcox, M. H., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa289 · Cited by 20
Self-citationIn vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
Abutaleb, N. S., & Seleem, M. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-86595-3 · Cited by 18
Ruzante, J. M., Olin, K., Muñoz, B., Nawrocki, J., Selvarangan, R., & Meyers, L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250767 · Cited by 21
Mendelsohn, R. B., Kaltsas, A., King, S. J., Hwang, C., Kassam, Z., Abend, A. M., Kramer, E., & Kamboj, M. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07024-z · Cited by 19
Yoo, I. H., Kang, H. M., Suh, W., Cho, H., Yoo, I. Y., Jo, S. J., Park, Y. J., & Jeong, D. C. (2021) · Diagnostics · doi:10.3390/diagnostics11071175 · Cited by 25
Fatemi, Y., & Bergl, P. A. (2021) · Critical Care Clinics · doi:10.1016/j.ccc.2021.09.002 · Cited by 19
Suchman, K., Luo, Y., & Grinspan, A. M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07347-x · Cited by 19
Clostridioides difficile infection and One Health: an equine perspective
Hain‐Saunders, N. M. R., Knight, D. R., Bruce, M., & Riley, T. V. (2022) · Environmental Microbiology · doi:10.1111/1462-2920.15898 · Cited by 21
Luo, Y., Zhang, S., Shang, H., Cui, W., Wang, Q., & Zhu, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.801475 · Cited by 23
“difficile or colonoscopic or histopathologic findings reveal ing pseudomembranous colitis (McDonald et al., 2018).”
BackgroundKwon, J., Kong, Y., Wade, M., Williams, D. J., Creech, C. B., Evans, S. R., Walter, E. B., Martin, J. M., Gerber, J. S., Newland, J. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac082 · Cited by 24
Merchante, N., Chico, P., Márquez-Saavedra, E., Riera, G., Herrero, R., González-de-la-Aleja, P., Aller, A. I., Rodríguez, J. C., Rodríguez-Fernández, M., Ramos, J. M., et al. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102579 · Cited by 19
Reveles, K. R., Frei, A., Strey, K. A., & Young, E. H. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac441 · Cited by 18
Krouss, M., Israilov, S., Alaiev, D., Tsega, S., Talledo, J., Chandra, K., Zaurova, M., Manchego, P. A., & Cho, H. J. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2022.11.003 · Cited by 18
Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State
Bhat, M. A., Mishra, A. K., Tantray, J. A., Alatawi, H. A., Saeed, M., Rahman, S., & Jan, A. T. (2022) · Life · doi:10.3390/life12121986 · Cited by 24
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Zhang, X., Ishikawa, D., Ohkusa, T., Fukuda, S., & Nagahara, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1068567 · Cited by 19
“In the Clostridioides difficile infection (CDI) treatment guidelines published in the United States and Europe, it is stated that FMT is a strongly recommended regimen for CDI with multiple recurrences (6, 7), with an effective rate of 92% (8).”
BackgroundTun, K. M., Hsu, M., Batra, K., Lo, C., Laeeq, T., Vongsavath, T., Mohammed, S., & Hong, A. S. (2022) · Microorganisms · doi:10.3390/microorganisms10122450 · Cited by 19
“Concerns have also been raised regarding SAE, such as transmission of multi-drug resistant organisms (MDRO), and blood-borne infections [35].”
Fecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level
Turner, N., Krishnan, J., Nelson, A. A., Polage, C. R., Cochran, R. L., Fike, L. V., Kuhar, D. T., Kutty, P. K., Snyder, R. L., & Anderson, D. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad334 · Cited by 18
Falcone, M., Tiseo, G., Iraci, F., Raponi, G., Goldoni, P., Rose, D. D., Santino, I., Carfagna, P., Murri, R., Fantoni, M., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.06.020 · Cited by 18
Legenza, L. M., Barnett, S. G., Rose, W. E., Safdar, N., Emmerling, T., Peh, K. H., & Coetzee, R. (2018) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-018-0425-y · Cited by 18
Acute and chronic non-pulmonary complications in adults with cystic fibrosis
Regard, L., Martin, C., Chassagnon, G., & Burgel, P. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1552832 · Cited by 22
Doll, M. E., Fleming, M. S., Stevens, M., & Bearman, G. M. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0659-8 · Cited by 18
Fecal microbiota transplantation in the ICU: perspectives on future implementations
Alagna, L., Haak, B. W., & Gori, A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05645-7 · Cited by 19
“While evidence-based consensus exists that the treatment is extremely effective against recurrent clostridium difficile infection (CDI), the use of FMT for this indication on the ICU remains controversial [9, 10].”
BackgroundImpact of a training program on the surveillance of Clostridioides difficile infection
Sopena, N., Freixas, N., Bella, F., Pérez, J. L., Hornero, A., Limon, E., Gudiol, F., Pujol, M., & the VINCat Clostridioides difficile study group (2019) · Epidemiology and Infection · doi:10.1017/s0950268819001080 · Cited by 19
Chiang, H., Huang, H.-C., Chung, C.-W., Yeh, Y., Chen, Y.-C., Tien, N., Lin, H.-S., Ho, M., & Kuo, C. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0642-z · Cited by 19
Nei, T., Hagiwara, J., Takiguchi, T., Yokobori, S., Kim, S., Yokota, H., Senoh, M., & Kato, H. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.10.021 · Cited by 19
Shah, M. D., Balada-Llasat, J.-M., Coe, K. E., Reed, E. E., Sandlund, J., & Pancholi, P. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01681-19 · Cited by 18
Pal, R., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-63029-0 · Cited by 19
Faecal microbiota transplantation as a home therapy to frail older people
Baunwall, S. M. D., Rubak, T., Damsgaard, E. M. S., Dahlerup, J. F., & Hvas, C. L. (2020) · Age and Ageing · doi:10.1093/ageing/afaa073 · Cited by 18
Shuai, H., Bian, Q., Luo, Y., Zhou, X., Song, X., Ye, J., Huang, Q., Peng, Z., Wu, J., Jiang, J., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05030-6 · Cited by 18
“Testing for CDI should be routinely standardized according to new clinical practice guidelines [13].”
BackgroundMethodBegum, K., Bassères, E., Miranda, J. M., Lancaster, C. K., Gonzales-Luna, A. J., Carlson, T. J., Rashid, T., Eyre, D. W., Wilcox, M. H., Alam, M. J., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00522-20 · Cited by 18
Self-citationDuration of Perioperative Antimicrobial Prophylaxis in Orthotopic Liver Transplantation Patients
Bandali, A., Bias, T. E., Lee, D. H., & Malat, G. E. (2020) · Progress in Transplantation · doi:10.1177/1526924820933824 · Cited by 18
Solanky, D., Juang, D. K., Johns, S. T., Drobish, I. C., Mehta, S. R., & Kumaraswamy, M. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.375 · Cited by 18
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna, S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13290 · Cited by 23
Emerging drugs for the treatment of clostridium difficile
Cammarota, G., Gallo, A., Ianiro, G., & Montalto, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591371 · Cited by 20
Consenso sobre prevención, diagnóstico y tratamiento de la infección por Clostridium difficile
y Abreu, A. T. A., Velasco, J. A. V.-R., Zavala-Solares, M. R., Remes-Troche, J. M., Carmona-Sánchez, R., Aldana-Ledesma, J. M., Camacho-Ortíz, A., Contreras-Omaña, R., Díaz-Seoane, R., Elizondo-Vázquez, C. T., et al. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.12.001 · Cited by 25
Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit
Kaviani, A., İnce, D., & Axelrod, D. A. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00268-0 · Cited by 18
Shen, J., Mehrotra, D. V., Dorr, M. B., Zeng, Z., Li, J., Xu, X., Nickle, D. C., Holzinger, E. R., Chhibber, A., Wilcox, M. H., et al. (2020) · mSphere · doi:10.1128/msphere.00232-20 · Cited by 19
“Current antibacterial treatment for primary CDI includes the use of vancomycin or fidaxomicin (4) and is often successful, with initial clinical cure rates commonly over 80% (5, 6).”
BackgroundSelf-citationPokhrel, A., Poudel, A., Castro, K. B., Celestine, M. J., Oludiran, A., Rinehold, A. J., Resek, A. M., Mhanna, M. A., & Purcell, E. B. (2020) · Journal of Bacteriology · doi:10.1128/jb.00377-20 · Cited by 17
Mitigating and managing infection risk in adults treated with CAR T-cell therapy
Tabbara, N., Dioverti, M. V., & Jain, T. (2024) · Hematology · doi:10.1182/hematology.2024000535 · Cited by 18
Alhifany, A. A., Almutairi, A. R., Almangour, T. A., Shahbar, A. N., Abraham, I. L., Alessa, M. Y., Alnezary, F. S., & Cheema, E. U. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031145 · Cited by 17
Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey
Vent‐Schmidt, J., Attara, G., Lisko, D. J., & Steiner, T. S. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s229539 · Cited by 17
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.